肝移植“精准”治疗原发性肝脏恶性肿瘤

doi:10.16139/j.1007-9610.2018.03.004

摘要/Abstract

中图分类号:

R735.7

李涛, 祝哲诚, 彭承宏. 肝移植“精准”治疗原发性肝脏恶性肿瘤[J]. 外科理论与实践, 2018, 23(03): 200-204.

[1] Starzl TE, Groth CG, Brettschneider L, et al.Orthotopic homotransplantation of the human liver[J]. Ann Surg,1968,168(3):392-415.
[2] Ringe B, Pichlmayr R, Wittekind C, et al.Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients[J]. World J Surg,1991,15(2):270-285.
[3] Mazzaferro V, Regalia E, Doci R, et al.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med,1996,334(11):693-699.
[4] Liu JB, Baker TB, Suss NR, et al.Orthotopic liver transplantation provides a survival advantage compared with resection in patients with hepatocellular carcinoma and preserved liver function[J]. Surgery,2017,162(5):1032-1039.
[5] Benjamin AJ, Baker TB, Talamonti MS, et al.Liver transplantation offers a survival benefit over margin negative resection in patients with small unifocal hepatocellular carcinoma and preserved liver function[J]. Surgery,2018,163(3):582-586.
[6] Yao FY, Ferrell L, Bass NM, et al.Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival[J]. Hepatology,2001,33(6):1394-1403.
[7] 樊嘉, 周俭, 徐泱, 等. 肝癌肝移植适应证的选择:上海复旦标准[J]. 中华医学杂志,2006,86(18):1227-1231.
[8] 徐骁, 杨家印, 钟林, 等. 肝癌肝移植"杭州标准"的多中心应用研究-1 163例报道[J]. 中华器官移植杂志,2013,34(9):524-527.
[9] Coletta M, Nicolini D, Cacciaguerra AB, et al.Bridging patients with hepatocellular cancer waiting for liver transplantion: all the patients are the same?[J]. Transl Gastroenterol Hepatol,2017,2:78.
[10] Lei J, Zhong J, Luo Y, et al.Response to transarterial chemoembolization may serve as selection criteria for hepatocellular carcinoma liver transplantation[J]. Oncotarget,2017,8(53):91328-91342.
[11] Castroagudín JF, Delgado M, Villanueva A, et al.Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates[J]. Transplant Proc,2005,37(9):3871-3873.
[12] Facciuto ME, Singh MK, Rochon C, et al.Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis: evaluation of radiological and pathological response[J]. J Surg Oncol,2012,105(7):692-698.
[13] Rubinstein MM, Kaubisch A, Kinkhabwala M, et al.Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation[J]. J Gastrointest Oncol,2017,8(6):1051-1055.
[14] Chua TC, Saxena A, Chu F, et al.Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria[J]. Am J Clin Oncol,2012,35(2):141-145.
[15] Bharat A, Brown DB, Crippin JS, et al.Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival[J]. J Am Coll Surg,2006,203(4):411-420.
[16] Chan KM, Yu MC, Chou HS, et al.Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation[J]. Ann Surg Oncol,2011,18(9):2638-2646.
[17] Majno P, Lencioni R, Mornex F, et al.Is the treatment of hepatocellular carcinoma on the waiting list necessary?[J]. Liver Transpl,2011,17(Suppl 2):S98-S108.
[18] Yao FY, Bass NM, Nikolai B, et al.A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy[J]. Liver Transpl,2003,9(7):684-692.
[19] European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: ma-nagement of hepatocellular carcinoma[J]. J Hepatol,2012, 56(4):908-943.
[20] Lee KW, Suh SW, Choi Y, et al.Macrovascular invasion is not an absolute contraindication for living donor liver transplantation[J]. Liver Transpl,2017,23(1):19-27.
[21] Li T, Xie J, Shen C, et al.Amplification of long nonco-ding RNA ZFAS1 promotes metastasis in hepatocellular carcinoma[J]. Cancer Res,2015,75(15):3181-3191.
[22] Li T, Xie J, Shen C, et al.Upregulation of long nonco-ding RNA ZEB1-AS1 promotes tumor metastasis and predicts poor prognosis in hepatocellular carcinoma[J]. Oncogene,2016,35(12):1575-1584.
[23] Allard MA, Sebagh M, Ruiz A, et al.Does pathological response after transarterial chemoembolization for hepatocellular carcinoma in cirrhotic patients with cirrhosis predict outcome after liver resection or transplantation?[J]. J Hepatol,2015,63(1):83-92.
[24] Lai Q, Avolio AW, Graziadei I, et al.Alpha-fetoprotein and modified response evaluation criteria in solid tumors progression after locoregional therapy as predictors of hepatocellular cancer recurrence and death after transplantation[J]. Liver Transpl,2013,19(10):1108-1118.
[25] Mehta N, Heimbach J, Harnois DM, et al.Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncol,2017,3(4):493-500.
[26] Otto G, Schuchmann M, Hoppe-Lotichius M, et al.How to decide about liver transplantation in patients with he-patocellular carcinoma: size and number of lesions or response to TACE?[J]. J Hepatol,2013,59(2):279-284.
[27] Duvoux C, Roudot-Thoraval F, Decaens T, et al.Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria[J]. Gastroenterology,2012,143(4):986-994.
[28] Lai Q, Nicolini D, Inostroza Nunez M, et al.A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: time-radiological-response-alpha-fetoprotein-inflammation(TRAIN) score[J]. Ann Surg,2016,264(5):787-796.
[29] Takada Y, Tohyama T, Watanabe J.Biological markers of hepatocellular carcinoma for use as selection criteria in liver transplantation[J]. J Hepatobiliary Pancreat Sci,2015,22(4):279-286.
[30] Sugawara Y, Tamura S, Makuuchi M.Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series[J]. Dig Dis,2007,25(4):310-312.
[31] Xia W, Ke Q, Guo H, et al.Expansion of the Milan criteria without any sacrifice: combination of the Hangzhou criteria with the pre-transplant platelet-to-lymphocyte ratio[J]. BMC Cancer,2017,17(1):14.
[32] Razumilava N, Gores GJ.Cholangiocarcinoma[J]. Lancet,2014,383(9935):2168-2179.
[33] Bridgewater J, Galle PR, Khan SA, et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol,2014,60(6):1268-1289.
[34] Mansour JC, Aloia TA, Crane CH, et al.Hilar cholangiocarcinoma: expert consensus statement[J]. HPB (Oxford),2015,17(8):691-699.
[35] Gores GJ, Darwish Murad S, Heimbach JK, et al.Liver transplantation for perihilar cholangiocarcinoma[J]. Dig Dis,2013,31(1):126-129.
[36] Ghali P, Marotta PJ, Yoshida EM, et al.Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience[J]. Liver Transpl,2005,11(11):1412-1416.
[37] Vilchez V, Shah MB, Daily MF, et al.Long-term outcome of patients undergoing liver transplantation for mixed hepatocellular carcinoma and cholangiocarcinoma: an analysis of the UNOS database[J]. HPB (Oxford),2016, 18(1):29-34.
[38] Facciuto ME, Singh MK, Lubezky N, et al.Tumors with intrahepatic bile duct differentiation in cirrhosis: implications on outcomes after liver transplantation[J]. Transplantation,2015,99(1):151-157.
[39] Sapisochin G, Facciuto M, Rubbia-Brandt L, et al.Liver transplantation for "very early" intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment[J]. Hepatology,2016,64(4):1178-1188.
[40] Sapisochin G, Rodríguez de Lope C, Gastaca M, et al. “Very early” intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients?[J]. Am J Transplant,2014,14(3):660-667.
[41] Sia D, Hoshida Y, Villanueva A, et al.Integrative mole-cular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes[J]. Gastroenterology,2013,144(4):829-840.
[42] Reyhan NH.Liver transplantation for nonhepatocellular carcinoma malignancy[J]. Exp Clin Transplant,2017, 15(Suppl 2):69-73.
[43] Czauderna P, Lopez-Terrada D, Hiyama E, et al.Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy[J]. Curr Opin Pediatr,2014, 26(1):19-28.
[44] Pritchard J, Brown J, Shafford E, et al.Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology[J]. J Clin Oncol,2000,18(22):3819-3828.
[45] Khaderi S, Guiteau J, Cotton RT, et al.Role of liver transplantation in the management of hepatoblastoma in the pediatric population[J]. World J Transplant,2014,4(4):294-298.
[46] Hackl C, Schlitt HJ, Kirchner GI, et al.Liver transplantation for malignancy: current treatment strategies and future perspectives[J]. World J Gastroenterology,2014,20(18):5331-5344.
[47] Kakar S, Burgart LJ, Batts KP, et al.Clinicopathologic features and survival in fibrolamellar carcinoma: comparison with conventional hepatocellular carcinoma with and without cirrhosis[J]. Mod Pathol,2005,18(11):1417-1423.
[48] Pinna AD, Iwatsuki S, Lee RG, et al.Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation[J]. Hepatology,1997,26(4):877-883.
[49] Stipa F, Yoon SS, Liau KH, et al.Outcome of patients with fibrolamellar hepatocellular carcinoma[J]. Cancer,2006,106(6):1331-1338.
[50] El-Gazzaz G, Wong W, El-Hadary MK, et al.Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma[J]. Transpl Int,2000,13(Suppl 1):S406-S409.
[51] Mavros MN, Mayo SC, Hyder O, et al.A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma[J]. J Am Col Surg,2012, 215(6):820-830.
[52] Kassahun WT.Contemporary management of fibrolamellar hepatocellular carcinoma: diagnosis, treatment, outcome, prognostic factors, and recent developments[J]. World J Surg Oncol,2016,14(1):151.
[53] Mehrabi A, Kashfi A, Fonouni H, et al.Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy[J]. Cancer,2006,107(9):2108-2121.
[54] Hibi T, Itano O, Shinoda M, et al.Liver transplantation for hepatobiliary malignancies: a new era of “Transplant Oncology” has begun[J]. Surg Today,2017,47(4):403-415.

肝移植“精准”治疗原发性肝脏恶性肿瘤

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨雪, 刘锦, 王铮, 陶杰, 郝杰, 李宇, 孙昊. 他克莫司降低肝移植病人ERCP术后胰腺炎发生的临床观察[J]. 外科理论与实践, 2022, 27(3): 253-255.
[2]	马婧嶔, 杨敏捷, 颜志平. 精细TACE的治疗目标与栓塞终点[J]. 外科理论与实践, 2022, 27(02): 131-133.
[3]	孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.
[4]	吴浩翔, 吕子成, 侯宇宸, 张子杰, 乔子耘, 冯浩, 夏强. 儿童肝移植中他克莫司浓度个体内变异[J]. 外科理论与实践, 2022, 27(02): 145-151.
[5]	张希昊, 章馨允, 曹曼卿, 张金梁, 王华琪, 张苏, 付周, 王鲁, 张倜. 肝细胞癌的抗血管生成免疫联合介入治疗：肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(02): 152-157.
[6]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦. 术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[7]	管涛(综述), 张倜, 王鲁(审校). 肝细胞癌肺转移的潜在机制和治疗进展[J]. 外科理论与实践, 2022, 27(02): 180-184.
[8]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[9]	冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.
[10]	李涛, 陈皓. 肝硬化门静脉高压症的肝移植治疗[J]. 外科理论与实践, 2021, 26(03): 189-194.
[11]	戚德彬, 陈鹏, 佟辉, 彭承宏, 李涛. 肝移植术后撤除免疫抑制剂的回顾性分析[J]. 外科理论与实践, 2021, 26(03): 231-235.
[12]	吴城孝, 方婕, 周霁川, 肖永胜, 张晓光. 基于TCGA数据库肝细胞癌microRNA-324-5p表达与预后危险因素分析[J]. 外科理论与实践, 2021, 26(03): 249-253.
[13]	黄成, 孙惠川. 《原发性肝癌诊疗规范（2019年版）》肝脏外科领域更新的展望[J]. 外科理论与实践, 2020, 25(01): 6-9.
[14]	佟辉, 陈鹏, 张家强, 谢俊杰, 李涛, 祝哲诚, 彭承宏. 加速康复外科在肝癌肝移植中的临床应用[J]. 外科理论与实践, 2020, 25(01): 45-49.
[15]	张勇强, 张倜, 孔银龙, 侯振宇, 李慧锴, 崔云龙, 宋天强, 李强. 术中出血对早期肝细胞癌病人围术期及预后的影响[J]. 外科理论与实践, 2018, 23(04): 342-345.